Prostate Cancer

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.

There was no difference in the occurrence of late toxicities between patients treated with radiotherapy alone or radiotherapy with short-term androgen deprivation therapy.

In an interview with Targeted Oncology, A. Oliver Sartor, MD, discussed the findings for subsequent 177Lu-PSMA following Radium-223 as treatment of patients with metastatic castration-resistant prostate cancer, as well as the next steps for this research.

The national RESPOND study is looking to determine potential underlying factors for the increased burden among African American males compared with American men of European descent and has identified novel variations among the African American population; however, an analysis from the study concluded that genomic alterations in known therapeutic targets show similar frequencies between the 2 racial groups.

Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.

"Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options."

In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.

Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.

“The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”

"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."

Thomas Hope, MD, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.

In an interview with Targeted Oncology following the American Urological Association Virtual Annual Meeting, Eric A. Klein, MD, discussed the importance of molecular testing in Caucasian and African American patients with newly diagnosed prostate cancer. He also discussed the pros and cons of active surveillance.

In an interview with Targeted Oncology, Aaron E. Katz, MD, FACS, discussed the findings from a study of the 17-gene Oncotype DX Genomic Prostate Score.

Alicia K. Morgans, MD, MPH, discussed treatment and testing strategies for metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses the design for an observational study of disease characteristics and outcome of patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA after receiving radium-223.

According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Patients with nonmetastatic castration-resistant prostate cancer receiving darolutamide plus androgen deprivation therapy had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival analysis presented during the 2020 ASCO Virtual Scientific Program.

"Liquid biopsies continue to gain attention in the field of oncology. The ability to have a rapid, noninvasive test, and one that allows for serial treatment monitoring is imperative for more precise patient care."

Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.

"The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."

"Relugolix is a novel, oral GnRH antagonist that has the potential to become a new standard for ADT in advanced prostate cancer."

“Lu-PSMA is a novel class of therapy with high activity and relatively low toxicity, consistent with the results of prior single-center studies in phase II data. Lu-PSMA appears to represent a favorable treatment option compared to cabazitaxel in a selected population with high PSMA-expression.”

Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.

In an interview with Targeted Oncology, following a tweet chat on prostate cancer, Tian Zhang, MD, discussed the key takeaways from the tweet chat discussion and highlighted both the role of molecular testing and the impact of the recent FDA approvals in prostate cancer.

Two companion diagnostic assays were granted FDA approval to identify male patients with metastatic castration-resistant prostate cancer who are eligible for treatment with olaparib.

The FDA has approved olaparib for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious germline or somatic HRR gene mutations and have progressed following prior treatment with a new hormonal agent.

“Although PARP inhibitor treatment has demonstrated radiographic and PSA responses in patients with BRCA alterations (4–8), the data presented here offer compelling evidence that response to PARP inhibitors is limited in men with mCRPC harboring an ATM, CDK1/2, or CHEK2 alteration."

Cabazitaxel demonstrated better patients-reported outcomes compared with either abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer.